Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a prominent pharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to commence clinical studies for its investigational drug KYS202004A for the treatment of psoriasis. This Category 1 biologic is a novel, dual-targeted fusion protein developed in-house, designed to manage the inflammatory response associated with psoriasis by simultaneously blocking the signaling pathways of TNF-α and IL-17A. This dual inhibition strategy is expected to reduce the production of downstream cytokines and chemokines, which are key mediators in the pathology of psoriasis.
Preclinical pharmacology studies have demonstrated that KYS202004A can significantly mitigate clinical symptoms such as skin erythema, dandruff, and thickening in crab eating monkey psoriasis models. Notably, at equivalent doses, KYS202004A has shown superior improvement effects compared to marketed drugs that target only a single pathway. Additionally, toxicological studies indicate that KYS202004A exhibits no drug-mediated non-specific toxic reactions and is well-tolerated, highlighting its potential as a safe and effective therapeutic option for patients with psoriasis. – Flcube.com
